Syros Pharmaceuticals Inc logo

Syros Pharmaceuticals Inc Share Price (NASDAQ: SYRS)

▲

-0.1

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 20 Mar 2025

Check the interactive Syros Pharmaceuticals Inc Stock chart to analyse performance

Syros Pharmaceuticals Inc Key Stats

Check Syros Pharmaceuticals Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.105
Open
$0.0686
Market Capitalization
$3.1M
Today's Volume
$2.9M
Revenue TTM
$386.0K
EBITDA
$-110.2M
Earnings Per Share (EPS)
$-3.07
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-776.96%

Global Institutional Holdings in Syros Pharmaceuticals Inc

  • Name

    Holdings %

  • Bain Capital Life Sciences Investors, LLC

    10.25%

  • BlackRock Inc

    1.03%

  • Vanguard Group Inc

    1.00%

  • Omega Fund Management LLC

    0.94%

  • Geode Capital Management, LLC

    0.73%

  • Affinity Asset Advisors, LLC

    0.56%

Analyst Recommendation on Syros Pharmaceuticals Inc Stock

Rating
Trend

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Syros Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Organization
Syros Pharmaceuticals Inc
Employees
68
CEO
Dr. James E. Bradner M.D.
Industry
Health Technology

Key Management of Syros Pharmaceuticals Inc

NameTitle
Dr. James E. Bradner M.D.
Founder
Dr. Nathanael S. Gray Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Matthew Foster
Chief Restructuring Officer

Important FAQs about investing in SYRS Stock from India :

What is Syros Pharmaceuticals Inc share price today?

Syros Pharmaceuticals Inc share price today is as on . Syros Pharmaceuticals Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Syros Pharmaceuticals Inc share?

Syros Pharmaceuticals Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Syros Pharmaceuticals Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Syros Pharmaceuticals Inc Stock (SYRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Syros Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Syros Pharmaceuticals Inc Shares .

What is the minimum amount required to buy Syros Pharmaceuticals Inc Stock (SYRS) from India?

Indian investors can start investing in Syros Pharmaceuticals Inc (SYRS) shares with as little as ₹88.185 or $1 (as of September 15, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.85 in Syros Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on September 15, 2025). Learn more about fractional shares .

What are the returns that Syros Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Syros Pharmaceuticals Inc stock has given 0.0% share price returns and 19.9% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?